10x Genomics (NASDAQ:TXG) Sets New 52-Week Low at $26.48

10x Genomics, Inc. (NASDAQ:TXG)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as $26.48 and last traded at $26.62, with a volume of 131771 shares trading hands. The stock had previously closed at $27.52.

Analysts Set New Price Targets

A number of equities research analysts have commented on TXG shares. Deutsche Bank Aktiengesellschaft reduced their target price on 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th. Stifel Nicolaus dropped their price objective on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Finally, Barclays dropped their price objective on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.22.

10x Genomics Trading Down 2.1 %

The company has a 50 day moving average of $38.54 and a 200 day moving average of $42.71.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The company had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. The company’s revenue for the quarter was up 17.8% compared to the same quarter last year. Analysts anticipate that 10x Genomics, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Transactions at 10x Genomics

In other news, insider Benjamin J. Hindson sold 2,613 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the completion of the transaction, the insider now directly owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Benjamin J. Hindson sold 2,613 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the completion of the transaction, the insider now directly owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Justin J. Mcanear sold 1,865 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the transaction, the chief financial officer now directly owns 95,240 shares of the company’s stock, valued at $4,413,421.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,959 shares of company stock valued at $592,806. 10.65% of the stock is currently owned by corporate insiders.

Institutional Trading of 10x Genomics

Institutional investors and hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of 10x Genomics by 113.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after purchasing an additional 371 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of 10x Genomics by 51.6% in the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock valued at $44,000 after purchasing an additional 266 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of 10x Genomics in the 4th quarter valued at about $66,000. Van ECK Associates Corp raised its stake in 10x Genomics by 23.4% during the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock valued at $107,000 after acquiring an additional 362 shares during the last quarter. Finally, Powell Investment Advisors LLC purchased a new stake in 10x Genomics during the 4th quarter valued at approximately $200,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.